Literature DB >> 17965419

Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.

Karen Fuenzalida1, Rodrigo Quintanilla, Patricio Ramos, Daniela Piderit, Rodrigo A Fuentealba, Gabriela Martinez, Nibaldo C Inestrosa, Miguel Bronfman.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) has been proposed as a therapeutic target for neurodegenerative diseases because of its anti-inflammatory action in glial cells. However, PPARgamma agonists preventbeta-amyloid (Abeta)-induced neurodegeneration in hippocampal neurons, and PPARgamma is activated by the nerve growth factor (NGF) survival pathway, suggesting a neuroprotective anti-inflammatory independent action. Here we show that the PPARgamma agonist rosiglitazone (RGZ) protects hippocampal and dorsal root ganglion neurons against Abeta-induced mitochondrial damage and NGF deprivation-induced apoptosis, respectively, and promotes PC12 cell survival. In neurons and in PC12 cells RGZ protective effects are associated with increased expression of the Bcl-2 anti-apoptotic protein. NGF-differentiated PC12 neuronal cells constitutively overexpressing PPARgamma are resistant to Abeta-induced apoptosis and morphological changes and show functionally intact mitochondria and no increase in reactive oxygen species when challenged with up to 50 microM H2O2. Conversely, cells expressing a dominant negative mutant of PPARgamma show increased Abeta-induced apoptosis and disruption of neuronal-like morphology and are highly sensitive to oxidative stress-induced impairment of mitochondrial function. Cells overexpressing PPARgamma present a 4- to 5-fold increase in Bcl-2 protein content, whereas in dominant negative PPARgamma-expressing cells, Bcl-2 is barely detected. Bcl-2 knockdown by small interfering RNA in cells overexpressing PPARgamma results in increased sensitivity to Abeta and oxidative stress, further suggesting that Bcl-2 up-regulation mediates PPARgamma protective effects. PPARgamma prosurvival action is independent of the signal-regulated MAPK or the Akt prosurvival pathways. Altogether, these data suggest that PPARgamma supports survival in neurons in part through a mechanism involving increased expression of Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965419     DOI: 10.1074/jbc.M700447200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  115 in total

1.  Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ.

Authors:  Chunhua Zhu; Songming Huang; Yanggang Yuan; Guixia Ding; Ronghua Chen; Bicheng Liu; Tianxin Yang; Aihua Zhang
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.

Authors:  Tristano Pancani; Jeremiah T Phelps; James L Searcy; Michael W Kilgore; Kuey-Chu Chen; Nada M Porter; Olivier Thibault
Journal:  J Neurochem       Date:  2009-05-11       Impact factor: 5.372

Review 3.  Amyloid beta-protein assembly and Alzheimer disease.

Authors:  Robin Roychaudhuri; Mingfeng Yang; Minako M Hoshi; David B Teplow
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

4.  Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors.

Authors:  Bridgette D Semple; Linda J Noble-Haeusslein
Journal:  Exp Neurol       Date:  2011-02-21       Impact factor: 5.330

5.  Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.

Authors:  Cynthia J M Kane; Kevin D Phelan; Lihong Han; Renea R Smith; Jin Xie; James C Douglas; Paul D Drew
Journal:  Brain Behav Immun       Date:  2011-03-03       Impact factor: 7.217

Review 6.  Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer's disease.

Authors:  Rupinder K Sodhi; Nirmal Singh; Amteshwar S Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-24       Impact factor: 3.000

7.  Effect of pioglitazone on neuropathic pain and spinal expression of TLR-4 and cytokines.

Authors:  Hongbin Jia; Shuangshuang Xu; Qingzhen Liu; Jian Liu; Jianguo Xu; Weiyan Li; Yi Jin; Qing Ji
Journal:  Exp Ther Med       Date:  2016-09-01       Impact factor: 2.447

Review 8.  Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.

Authors:  Juan M Zolezzi; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

9.  Peroxisome Proliferator-Activated Receptors Protect against Apoptosis via 14-3-3.

Authors:  Kenneth K Wu
Journal:  PPAR Res       Date:  2010-08-24       Impact factor: 4.964

10.  Staging anti-inflammatory therapy in Alzheimer's disease.

Authors:  Mathieu P Lichtenstein; Paulina Carriba; Roser Masgrau; Aurora Pujol; Elena Galea
Journal:  Front Aging Neurosci       Date:  2010-10-25       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.